Ukmedix News has seen how effective the weight loss drug Acomplia can be...

Despite showing lower 1st quarter results the drug manufacturer Sanofi-Aventis has raised its final year profit forecast partly on the basis that the weight loss drug Acomplia should be OK'ed for sale in the United States of America.

These are nervous times for Sanofi Aventis who have staked much on the weight loss drug Acomplia and whose future viability will be very much determined in June when a special FDA panel meets to decide whether or not to approve this new diet drug. The approval has been put off time and time again and is about a year late. If the FDA approval comes through the stock of Sanofi Aventis should rise considerably and should the approval not be forthcoming the stock will almost certainly fall.

Acomplia is a novel weight loss drug in that it acts on the brain receptors that control appetite and hunger pangs and its development involved many millions of pounds worth of research. The drug has been extensively tested and on the basis of these clinical trials the EMEA of the European Union, the Acomplia drug has been given full approval for sale and marketing.

The first country in the European Union to allow the sale of Acomplia was the United Kingdom which has been selling it since the month of June 2006. There is a big demand for Acomplia from the United States where the levels of obesity have attained an all time high and are the highest levels in the world.

Ukmedix News has seen how effective the weight loss drug Acomplia can be in helping obese people shed the pounds. Sanofi Aventis also say that Acomplia can help people who suffer from the symptoms of diabetes. Obesity is extremely dangerous and causes a huge amount of health conditions such as heart disease, diabetes and hypertension.